RT Journal Article
SR Electronic
T1 Single-cell dissection of schizophrenia reveals neurodevelopmental-synaptic axis and transcriptional resilience
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.06.20225342
DO 10.1101/2020.11.06.20225342
A1 Ruzicka, W. Brad
A1 Mohammadi, Shahin
A1 Davila-Velderrain, Jose
A1 Subburaju, Sivan
A1 Tso, Daniel Reed
A1 Hourihan, Makayla
A1 Kellis, Manolis
YR 2020
UL http://medrxiv.org/content/early/2020/11/09/2020.11.06.20225342.abstract
AB Schizophrenia is a devastating mental disorder with a high societal burden, complex pathophysiology, and diverse genetic and environmental risk factors. Its complexity, polygenicity, and small-effect-size and cell-type-specific contributors have hindered mechanistic elucidation and the search for new therapeutics. Here, we present the first single-cell dissection of schizophrenia, across 500,000+ cells from 48 postmortem human prefrontal cortex samples, including 24 schizophrenia cases and 24 controls. We annotate 20 cell types/states, providing a high-resolution atlas of schizophrenia-altered genes and pathways in each. We find neurons are the most affected cell type, with deep-layer cortico-cortical projection neurons and parvalbumin-expressing inhibitory neurons showing significant transcriptional changes converging on genetically-implicated regions. We discover a novel excitatory-neuron cell-state indicative of transcriptional resilience and enriched in schizophrenia subjects with less-perturbed transcriptional signatures. We identify key trans-acting factors as candidate drivers of observed transcriptional perturbations, including MEF2C, TCF4, SOX5, and SATB2, and map their binding patterns in postmortem human neurons. These factors regulate distinct gene sets underlying fetal neurodevelopment and adult synaptic function, bridging two leading models of schizophrenia pathogenesis. Our results provide the most detailed map to date for mechanistic understanding and therapeutic development in neuropsychiatric disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Wilf Family Foundations and by NIH grant K08MH109759 (W.B.R.) and by NIH grants 1U01MH119509, R01MH109978, and R01AG062335 (M.K.). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board approval was obtained by the Harvard Brain Tissue Resource Center for the collection, storage, and distribution of brain tissue and de-identified clinical information for each case.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMULTI-seq data are available at Synapse (https://www.synapse.org/#!Synapse:syn22963646). The data are available under controlled use conditions set by human data privacy regulations, and access requires a data use agreement to ensure the anonymity of the donors of postmortem human brain tissue. A data use agreement can be pursued with SAGE, who maintains Synapse and can be downloaded from their website.